Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients

Viveros, Martha Eva; Areán, Carlos; Gutiérrez, Sergio; Vázquez, Soledad; Cardiel, Mario Humberto; Taboada, Alejandra; Marín, Gissela; Solorio, Ruben; García, Nalley.
Arch. cardiol. Méx ; 86(4): 297-304, oct.-dic. 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-838392

Documentos relacionados

  1. Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians.
  2. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
  3. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis.
  4. Is <i>CYP2C</i> Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
  5. Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population.
  6. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
  7. The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population.
  8. Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients.
  9. Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement.
  10. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.